Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 31, 2023 06:00 ET | Source: Invectys, Inc.

FDA Grants Fast Track designation to IVS-3001, a CAR-T Cell Therapy in the Treatment of Renal Cell Carcinoma

Houston, TX, USA, July 31, 2023 (GLOBE NEWSWIRE) -- Invectys, Inc., a clinical-stage immuno-oncology company focused on developing novel therapies for advanced cancers, is pleased to announce the...
July 13, 2023 09:08 ET | Source: Invectys, Inc.

Invectys Announces Initiation of Phase 1/2a Clinical Trial in Solid Tumors and Change in Leadership

Houston, TX, USA, July 13, 2023 (GLOBE NEWSWIRE) -- Invectys, Inc., a clinical-stage immuno-oncology company developing novel therapies for the treatment of advanced cancers, today announces it has...
January 05, 2023 08:00 ET | Source: Invectys, Inc.

INVECTYS, INC. TO PARTICIPATE IN THE 41st JP MORGAN HEALTHCARE CONFERENCE ON JANUARY 9-12, 2023

Houston, Texas, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Invectys, Inc. “Invectys”, a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development of a new generation of...
December 20, 2022 08:50 ET | Source: Invectys, Inc.

Updated Invectys and CTMC announce FDA clearance of IND application for anti-HLA-G CAR-T cell therapy

FDA granted IND clearance for IVS-3001, Invectys’s lead engineered anti-HLA-G CAR-T cell therapy, for the treatment of patients with solid tumors HOUSTON, Texas, Dec. 20, 2022 (GLOBE NEWSWIRE) --...
December 19, 2022 10:24 ET | Source: Invectys, Inc.

Invectys and CTMC announce FDA clearance of IND application for anti-HLA-G CAR-T cell therapy

FDA granted IND clearance for IVS-3001, Invectys’s lead engineered anti-HLA-G CAR-T cell therapy, for the treatment of patients with solid tumorsHOUSTON, Texas, Dec. 19, 2022 (GLOBE NEWSWIRE) --...
June 16, 2022 09:00 ET | Source: Invectys, Inc.

INVECTYS, MD ANDERSON AND CTMC ANNOUNCE STRATEGIC COLLABORATION FOR CAR T CELL THERAPY DEVELOPMENT

HOUSTON, June 16, 2022 (GLOBE NEWSWIRE) -- Invectys, Inc. (Invectys), The University of Texas MD Anderson Cancer Center and the Cell Therapy Manufacturing Center (CTMC), a joint venture between...
May 12, 2022 10:00 ET | Source: Invectys, Inc.

Invectys appoints Timothy Papp as its Chief Financial Officer

Houston, Texas, USA, May 12, 2022 (GLOBE NEWSWIRE) -- Invectys, Inc. of Houston, Texas, a clinical stage immunotherapy company dedicated to the development of a next generation of therapies to meet...
April 11, 2022 10:00 ET | Source: Invectys, Inc.

Invectys, Inc. Appoints François Lescure as General Manager of its R&D Subsidiary, Invectys, SAS

Houston, Texas, USA, April 11, 2022 (GLOBE NEWSWIRE) -- Invectys, Inc. of Houston, Texas, a clinical stage immunotherapy company which is developing a next generation of therapies to meet the needs...
March 09, 2022 10:00 ET | Source: Invectys, Inc.

Wayne A. Marasco, M.D., Ph.D. joins Invectys’ Scientific Advisory Board

Houston, Texas, USA, March 09, 2022 (GLOBE NEWSWIRE) -- Invectys, Inc. of Houston, Texas, a clinical stage immunotherapy company dedicated to the development of a next generation of therapies to...
March 01, 2022 09:15 ET | Source: Invectys, Inc.

Invectys appoints Jian Cao, Ph.D., as Vice President, Pharmaceutical Development

Houston, Texas, USA, March 01, 2022 (GLOBE NEWSWIRE) -- Invectys, Inc. of Houston, Texas, a clinical stage immunotherapy company dedicated to the development of a next generation of therapies to...

Next Page keyboard_arrow_right